Stock A185750 CHONG KUN DANG PHARMACEUTICAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Chong Kun Dang Pharmaceutical Corp.

Equities

A185750

KR7185750007

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
110,600 KRW +3.46% Intraday chart for Chong Kun Dang Pharmaceutical Corp. +10.49% -15.51%
Apr. 25 Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on January 23, 2024. CI
Jan. 23 Chong Kun Dang Pharmaceutical Corp. announces an Equity Buyback for KRW 15,000 million worth of its shares. CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • With regards to fundamentals, the enterprise value to sales ratio is at 914.16 for the current period. Therefore, the company is undervalued.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHONG KUN DANG PHARMACEUTICAL CORP. Stock Chong Kun Dang Pharmaceutical Corp.
-15.51% 1.03B -
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+25.24% 45.32B
B-
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+34.85% 24.51B
B+
SANDOZ GROUP AG Stock Sandoz Group AG
+29.56% 16.85B -
CIPLA LIMITED Stock Cipla Limited
+21.32% 14.62B
B+
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+70.51% 14.16B
B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B - -
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+15.74% 5.82B
B+
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B - -
GEDEON RICHTER Stock Gedeon Richter
+10.29% 4.93B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A185750 Stock
  4. Ratings Chong Kun Dang Pharmaceutical Corp.